Cargando…
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
RATIONALE: Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psychedelics have recently reemerged as a potential therapeutic treatment option. OBJECTIVE: We present the first meta-analytic review evaluating the clinical effects of classic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826317/ https://www.ncbi.nlm.nih.gov/pubmed/33427944 http://dx.doi.org/10.1007/s00213-020-05719-1 |
_version_ | 1783640511755583488 |
---|---|
author | Galvão-Coelho, Nicole L. Marx, Wolfgang Gonzalez, Maria Sinclair, Justin de Manincor, Michael Perkins, Daniel Sarris, Jerome |
author_facet | Galvão-Coelho, Nicole L. Marx, Wolfgang Gonzalez, Maria Sinclair, Justin de Manincor, Michael Perkins, Daniel Sarris, Jerome |
author_sort | Galvão-Coelho, Nicole L. |
collection | PubMed |
description | RATIONALE: Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psychedelics have recently reemerged as a potential therapeutic treatment option. OBJECTIVE: We present the first meta-analytic review evaluating the clinical effects of classic serotonergic psychedelics vs placebo for mood state and symptoms of depression in both healthy and clinical populations (separately). RESULTS: Our search revealed 12 eligible studies (n = 257; 124 healthy participants, and 133 patients with mood disorders), with data from randomized controlled trials involving psilocybin (n = 8), lysergic acid diethylamide ([LSD]; n = 3), and ayahuasca (n = 1). The meta-analyses of acute mood outcomes (3 h to 1 day after treatment) for healthy volunteers and patients revealed improvements with moderate significant effect sizes in favor of psychedelics, as well as for the longer-term (16 to 60 days after treatments) mood state of patients. For patients with mood disorder, significant effect sizes were detected on the acute, medium (2–7 days after treatment), and longer-term outcomes favoring psychedelics on the reduction of depressive symptoms. CONCLUSION: Despite the concerns over unblinding and expectancy, the strength of the effect sizes, fast onset, and enduring therapeutic effects of these psychotherapeutic agents encourage further double-blind, placebo-controlled clinical trials assessing them for management of negative mood and depressive symptoms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00213-020-05719-1. |
format | Online Article Text |
id | pubmed-7826317 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-78263172021-02-11 Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants Galvão-Coelho, Nicole L. Marx, Wolfgang Gonzalez, Maria Sinclair, Justin de Manincor, Michael Perkins, Daniel Sarris, Jerome Psychopharmacology (Berl) Review RATIONALE: Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psychedelics have recently reemerged as a potential therapeutic treatment option. OBJECTIVE: We present the first meta-analytic review evaluating the clinical effects of classic serotonergic psychedelics vs placebo for mood state and symptoms of depression in both healthy and clinical populations (separately). RESULTS: Our search revealed 12 eligible studies (n = 257; 124 healthy participants, and 133 patients with mood disorders), with data from randomized controlled trials involving psilocybin (n = 8), lysergic acid diethylamide ([LSD]; n = 3), and ayahuasca (n = 1). The meta-analyses of acute mood outcomes (3 h to 1 day after treatment) for healthy volunteers and patients revealed improvements with moderate significant effect sizes in favor of psychedelics, as well as for the longer-term (16 to 60 days after treatments) mood state of patients. For patients with mood disorder, significant effect sizes were detected on the acute, medium (2–7 days after treatment), and longer-term outcomes favoring psychedelics on the reduction of depressive symptoms. CONCLUSION: Despite the concerns over unblinding and expectancy, the strength of the effect sizes, fast onset, and enduring therapeutic effects of these psychotherapeutic agents encourage further double-blind, placebo-controlled clinical trials assessing them for management of negative mood and depressive symptoms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00213-020-05719-1. Springer Berlin Heidelberg 2021-01-11 2021 /pmc/articles/PMC7826317/ /pubmed/33427944 http://dx.doi.org/10.1007/s00213-020-05719-1 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Galvão-Coelho, Nicole L. Marx, Wolfgang Gonzalez, Maria Sinclair, Justin de Manincor, Michael Perkins, Daniel Sarris, Jerome Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants |
title | Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants |
title_full | Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants |
title_fullStr | Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants |
title_full_unstemmed | Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants |
title_short | Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants |
title_sort | classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826317/ https://www.ncbi.nlm.nih.gov/pubmed/33427944 http://dx.doi.org/10.1007/s00213-020-05719-1 |
work_keys_str_mv | AT galvaocoelhonicolel classicserotonergicpsychedelicsformoodanddepressivesymptomsametaanalysisofmooddisorderpatientsandhealthyparticipants AT marxwolfgang classicserotonergicpsychedelicsformoodanddepressivesymptomsametaanalysisofmooddisorderpatientsandhealthyparticipants AT gonzalezmaria classicserotonergicpsychedelicsformoodanddepressivesymptomsametaanalysisofmooddisorderpatientsandhealthyparticipants AT sinclairjustin classicserotonergicpsychedelicsformoodanddepressivesymptomsametaanalysisofmooddisorderpatientsandhealthyparticipants AT demanincormichael classicserotonergicpsychedelicsformoodanddepressivesymptomsametaanalysisofmooddisorderpatientsandhealthyparticipants AT perkinsdaniel classicserotonergicpsychedelicsformoodanddepressivesymptomsametaanalysisofmooddisorderpatientsandhealthyparticipants AT sarrisjerome classicserotonergicpsychedelicsformoodanddepressivesymptomsametaanalysisofmooddisorderpatientsandhealthyparticipants |